Effektivnost' nizkikh doz gemtsitabina v kombinatsii s tsisplatinom v lechenii disseminirovannogo raka molochnoy zhelezy s progressirovaniem posle primeneniya antratsiklinov, taksanov i kapetsitabina

The article is dedicated to the examination of efficacy and toxicity of combination chemotherapy with low-dose gemcitabine and cispla-tin in 131 patients with metastatic breast cancer (BC) progressing after application of anthracycline antibiotics, taxanes, capecitabine, and other cytotoxic agents. Gemcitabine was administered intravenously by drop infusion at a dose of 600-750 mg/m2, cisplatin - at a dose 30 mg/m2 on the 1st and 8th days every 3 weeks. The combination of gemcitabine with cisplatin at low doses was effective in the treatment of metastatic breast cancer not only in the 2nd, but in the 3rd, 4th, and subsequent lines of chemotherapy, and can be used to produce repeat therapeutic effects against the background of exhausted possibilities of drug treatment with anthracycline, taxanes, capecitabine, and other anticancer agents. Moderate and predictable toxicity, that does not require dose reduction and allows to use multiple courses of chemotherapy, as well as in elderly and debilitated patients with metastatic breast cancer, including in outpatient settings, are the advantage of application of gemcitabine with cisplatin.

breast cancer, gemcitabine, cisplatin, anthracyclines, taxanes, capecitabine